Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies

Mary P. Lambert, Kirsten L. Viola, Brett A. Chromy, Lei Chang, Todd E. Morgan, Jiaxin Yu, Duane L. Venton, Grant A. Krafft, Caleb E. Finch, William L. Klein

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Aβ1-42) solutions (mixtures of Aβ monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Aβ. It is now known that Aβ toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Aβ1-42 oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Aβ1-42 solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Aβ in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell 'culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immunoneutralization of soluble Aβ-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.

Original languageEnglish (US)
Pages (from-to)595-605
Number of pages11
JournalJournal of Neurochemistry
Volume79
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Neutralizing Antibodies
Oligomers
Toxicity
Vaccination
Amyloid
Antibodies
Alzheimer Vaccines
Immunization
Alzheimer Disease
Peptides
Amyloid Plaques
Transgenic Mice
Fluorescent Antibody Technique
Monomers
Cell Culture Techniques
Rabbits
Amyloid beta-Peptides
Brain
Cell culture
Assays

Keywords

  • ADDLs
  • Alzheimer's disease
  • Receptors
  • Therapeutic drugs
  • Vaccination

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., ... Klein, W. L. (2001). Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. Journal of Neurochemistry, 79(3), 595-605. https://doi.org/10.1046/j.1471-4159.2001.00592.x

Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. / Lambert, Mary P.; Viola, Kirsten L.; Chromy, Brett A.; Chang, Lei; Morgan, Todd E.; Yu, Jiaxin; Venton, Duane L.; Krafft, Grant A.; Finch, Caleb E.; Klein, William L.

In: Journal of Neurochemistry, Vol. 79, No. 3, 2001, p. 595-605.

Research output: Contribution to journalArticle

Lambert, MP, Viola, KL, Chromy, BA, Chang, L, Morgan, TE, Yu, J, Venton, DL, Krafft, GA, Finch, CE & Klein, WL 2001, 'Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies', Journal of Neurochemistry, vol. 79, no. 3, pp. 595-605. https://doi.org/10.1046/j.1471-4159.2001.00592.x
Lambert, Mary P. ; Viola, Kirsten L. ; Chromy, Brett A. ; Chang, Lei ; Morgan, Todd E. ; Yu, Jiaxin ; Venton, Duane L. ; Krafft, Grant A. ; Finch, Caleb E. ; Klein, William L. / Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. In: Journal of Neurochemistry. 2001 ; Vol. 79, No. 3. pp. 595-605.
@article{91ea623798db4ec4b6ce91038ffe0c1e,
title = "Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies",
abstract = "In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Aβ1-42) solutions (mixtures of Aβ monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Aβ. It is now known that Aβ toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Aβ1-42 oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Aβ1-42 solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Aβ in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell 'culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immunoneutralization of soluble Aβ-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.",
keywords = "ADDLs, Alzheimer's disease, Receptors, Therapeutic drugs, Vaccination",
author = "Lambert, {Mary P.} and Viola, {Kirsten L.} and Chromy, {Brett A.} and Lei Chang and Morgan, {Todd E.} and Jiaxin Yu and Venton, {Duane L.} and Krafft, {Grant A.} and Finch, {Caleb E.} and Klein, {William L.}",
year = "2001",
doi = "10.1046/j.1471-4159.2001.00592.x",
language = "English (US)",
volume = "79",
pages = "595--605",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies

AU - Lambert, Mary P.

AU - Viola, Kirsten L.

AU - Chromy, Brett A.

AU - Chang, Lei

AU - Morgan, Todd E.

AU - Yu, Jiaxin

AU - Venton, Duane L.

AU - Krafft, Grant A.

AU - Finch, Caleb E.

AU - Klein, William L.

PY - 2001

Y1 - 2001

N2 - In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Aβ1-42) solutions (mixtures of Aβ monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Aβ. It is now known that Aβ toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Aβ1-42 oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Aβ1-42 solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Aβ in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell 'culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immunoneutralization of soluble Aβ-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.

AB - In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Aβ1-42) solutions (mixtures of Aβ monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Aβ. It is now known that Aβ toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Aβ1-42 oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Aβ1-42 solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Aβ in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell 'culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immunoneutralization of soluble Aβ-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.

KW - ADDLs

KW - Alzheimer's disease

KW - Receptors

KW - Therapeutic drugs

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0034740197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034740197&partnerID=8YFLogxK

U2 - 10.1046/j.1471-4159.2001.00592.x

DO - 10.1046/j.1471-4159.2001.00592.x

M3 - Article

VL - 79

SP - 595

EP - 605

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 3

ER -